Scientific and Medical Equipment House

As of June 30, 2026, Scientific and Medical Equipment House carries a market capitalization of 881.40M, placing it among publicly traded companies globally. Its enterprise value stands at 1.02B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Scientific and Medical Equipment House's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Scientific and Medical Equipment House has 30.00M shares outstanding.

As of June 30, 2026, Scientific and Medical Equipment House trades at a trailing price-to-earnings ratio of 32.00. The price-to-sales ratio is 1.12, and the price-to-book ratio stands at 1.77.

As of June 30, 2026, Scientific and Medical Equipment House trades at an EV/EBITDA multiple of 20.29 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.30 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 29.37 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Scientific and Medical Equipment House trades at an EV/FCF ratio of 11.57, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 1.02B versus a market cap of 881.40M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Scientific and Medical Equipment House maintains a current ratio of 2.15, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 47.48, indicating elevated leverage, while an interest coverage ratio of 2.70 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Scientific and Medical Equipment House posted a return on equity (ROE) of 5.35, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 3.35 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 2.77, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 5.92, useful for judging operating efficiency across full business cycles. Inventory turnover of 10.86 indicates how many times Scientific and Medical Equipment House sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Scientific and Medical Equipment House recorded 11.03M in income tax expense. That works out to an effective tax rate of 30.24, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 36.46M, leaving 27.54M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Scientific and Medical Equipment House's stock has declined approximately 32.40% over the past 52 weeks. The 50-day moving average sits at 27.21, while the 200-day moving average is 29.59.

Over the twelve months ended June 30, 2026, Scientific and Medical Equipment House generated 786.45M in revenue and converted that into 27.54M in net income, yielding earnings per share of 0.85. EBITDA reached 50.52M, while operating income came in at 34.94M.

As of June 30, 2026, Scientific and Medical Equipment House holds 80.36M in cash and equivalents against 232.66M in total debt, resulting in a net debt position of 139.82M. Total book value stands at 498.71M, with working capital of 493.35M providing operational flexibility.

Scientific and Medical Equipment House produced 81.43M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -5.91M in capital expenditures, free cash flow totaled 75.52M - equivalent to 2.52 per share.

Over the twelve months ended June 30, 2026, Scientific and Medical Equipment House posted a gross margin of 13.93, reflecting its pricing power and cost economics. The operating margin of 4.44 and net profit margin of 3.50 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Scientific and Medical Equipment House paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 8.57, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.24, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Scientific and Medical Equipment House shareholders.

Scientific and Medical Equipment House's most recent stock split took place on September 4, 2023 with a 2:3 split ratio.

As of June 30, 2026, Scientific and Medical Equipment House has an Altman Z-Score of 2.73, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.